Triptolide Inhibits Histone Methyltransferase EZH2 and Modulates the Expression of Its Target Genes in Prostate Cancer Cells

被引:31
|
作者
Tamgue, Ousman [1 ,2 ]
Chai, Cheng-Sen [1 ]
Hao, Lin [1 ]
Zambe, John-Clotaire Daguia [1 ]
Huang, Wei-Wei [1 ]
Zhang, Bin [1 ]
Lei, Ming [1 ]
Wei, Yan-Ming [1 ]
机构
[1] Northwest A&F Univ, Coll Life Sci, Key Lab Agr Mol Biol, Yangling, Peoples R China
[2] Univ Yaounde I, Dept Biochem, Lab Biochem & study Med Plants, Yaounde, Cameroon
关键词
EZH2; EZH2 target genes; prostate cancer (PCa); Triptolide; GROUP PROTEIN EZH2; POLYCOMB GROUP PROTEINS; METHYLATION; EPIGENETICS; PROGRESSION;
D O I
10.7314/APJCP.2013.14.10.5663
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The histone methyltransferase EZH2 (enhancer of zeste homolog 2) plays critical roles in prostate cancer (PCa) development and is a potential target for PCa treatment. Triptolide possesses anti-tumor activity, but it is unknown whether its therapeutic effect relates with EZH2 in PCa. Here we described EZH2 as a target for Triptolide in PCa cells. Our data showed that Triptolide suppressed PCa cell growth and reduced the expression of EZH2. Overexpression of EZH2 attenuated the Triptolide induced cell growth inhibition. Moreover, Triptolide treatment of PC-3 cells resulted in elevated mRNA levels of target genes (ADRB2, CDH1, CDKN2A and DAB2IP) negatively regulated by EZH2 as well as reduced mRNA levelsan of EZH2 positively regulated gene (cyclin D1). Our findings suggest the PCa cell growth inhibition mediated by Triptolide might be associated with downregulation of EZH2 expression and the subsequent modulation of target genes.
引用
收藏
页码:5663 / 5669
页数:7
相关论文
共 50 条
  • [31] Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
    Edward Curry
    Ian Green
    Nadine Chapman-Rothe
    Elham Shamsaei
    Sarah Kandil
    Fanny L Cherblanc
    Luke Payne
    Emma Bell
    Thota Ganesh
    Nitipol Srimongkolpithak
    Joachim Caron
    Fengling Li
    Anthony G. Uren
    James P. Snyder
    Masoud Vedadi
    Matthew J. Fuchter
    Robert Brown
    Clinical Epigenetics, 2015, 7
  • [32] Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
    Brown, R.
    Fuchter, M.
    Curry, E.
    Green, I.
    Kandil, S.
    Cherblanc, F.
    Payne, L.
    Chapman-Rothe, N.
    Shamsaei, E.
    Srimongkolpithak, N.
    Snyder, J.
    Vedadi, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 179 - 180
  • [33] Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
    Curry, Edward
    Green, Ian
    Chapman-Rothe, Nadine
    Shamsaei, Elham
    Kandil, Sarah
    Cherblanc, Fanny L.
    Payne, Luke
    Bell, Emma
    Ganesh, Thota
    Srimongkolpithak, Nitipol
    Caron, Joachim
    Li, Fengling
    Uren, Anthony G.
    Snyder, James P.
    Vedadi, Masoud
    Fuchter, Matthew J.
    Brown, Robert
    CLINICAL EPIGENETICS, 2015, 7
  • [34] TSPYL2 Regulates the Expression of EZH2 Target Genes in Neurons
    Hang Liu
    Lei Peng
    Joan So
    Ka Hing Tsang
    Chi Ho Chong
    Priscilla Hoi Shan Mak
    Kui Ming Chan
    Siu Yuen Chan
    Molecular Neurobiology, 2019, 56 : 2640 - 2652
  • [35] Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo
    Kuang, Yan
    Lu, Fangfang
    Guo, Jianfeng
    Xu, Hong
    Wang, Qi
    Xu, Chaohuan
    Zeng, Longjia
    Yi, Suyi
    ONCOTARGETS AND THERAPY, 2017, 10 : 3131 - 3144
  • [36] TSPYL2 Regulates the Expression of EZH2 Target Genes in Neurons
    Liu, Hang
    Peng, Lei
    So, Joan
    Tsang, Ka Hing
    Chong, Chi Ho
    Mak, Priscilla Hoi Shan
    Chan, Kui Ming
    Chan, Siu Yuen
    MOLECULAR NEUROBIOLOGY, 2019, 56 (04) : 2640 - 2652
  • [37] EFFECTS OF COMBINED EPIGENETIC THERAPY WITH THE HISTONE METHYLTRANSFERASE EZH2 INHIBITOR AND THE HISTONE DEACETYLASE INHIBITOR ON NSCLC CELLS
    Takashina, Taichi
    Kinoshita, Ichiro
    Kikuchi, Junko
    Kikuchi, Eiki
    Shimizu, Yasushi
    Sakakibara-Konishi, Jyunn
    Oizumi, Satoshi
    Nishimura, Masaharu
    Akita, Hirotoshi D.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S434 - S434
  • [38] EZH2 controls neuroblastoma survival via actively regulates MYCN target genes without its methyltransferase activity
    Tsubota, Shoma
    Kadomatsu, Kenji
    CANCER SCIENCE, 2022, 113 : 1499 - 1499
  • [39] EZH2 promotes proliferation and invasiveness of prostate cancer cells
    Bryant, R. J.
    Cross, N. A.
    Eaton, C. L.
    Hamdy, F. C.
    Cunliffe, V. T.
    PROSTATE, 2007, 67 (05): : 547 - 556
  • [40] Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells
    Kikuchi, Junko
    Takashina, Taichi
    Kinoshita, Ichiro
    Kikuchi, Eiki
    Shimizu, Yasushi
    Sakakibara-Konishi, Jun
    Oizumi, Satoshi
    Marquez, Victor E.
    Nishimura, Masaharu
    Dosaka-Akita, Hirotoshi
    LUNG CANCER, 2012, 78 (02) : 138 - 143